H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs PharmaCare U.S., Inc.

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
PharmaCare U.S., Inc.
CARank #FEIN 27-0557891

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPPharmaCare U.S., Inc.
Total filings80,813387
Certified %98.23%83.20%
Denied %1.09%1.29%
Withdrawn %0.61%4.65%
Cert-withdrawn %0.07%10.85%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2025
Worksite statePACA

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — PharmaCare U.S., Inc.

DOL case-status mix.

Outcome breakdown: Certified 83.2%, Cert-withdrawn 10.9%, Withdrawn 4.7%, Denied 1.3%
Outcome breakdown
OutcomeShare
Certified83.2%
Cert-withdrawn10.9%
Withdrawn4.7%
Denied1.3%
Certified83.2%
Cert-withdrawn10.9%
Withdrawn4.7%
Denied1.3%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
PharmaCare U.S., Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201035
FY201153
FY201249
FY201363
FY201439
FY201542
FY201630
FY201724
FY201829
FY201920
FY20202
FY20210
FY20220
FY20230
FY20240
FY20251
FY20260

Top 5 occupations — Deloitte Consulting LLP

Top 5 occupations — PharmaCare U.S., Inc.

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.